1
Aug

Nicole Simone, M.D., Receives ASTRO Research Award

The American Society for Radiation Oncology (ASTRO) has awarded five physicians with research grants to promote the continued advancement of radiation therapy. One of this year’s recipient for the Junior Faculty Career Research Training Award is Nicole L. Simone, M.D., of the Department of Radiation Oncology at Thomas Jefferson University Hospital. The Junior Faculty Award …

26
Jul

Breast Cancer Patients Who Lack RB Gene Respond Better to Neoadjuvant Chemotherapy

Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research. Many breast cancer patients undergo neoadjuvant therapy …

28
Jun

ATP: From Bystander to Actor in Kinase Regulation

A new function of ATP—beyond its passive roles as an energy source and a phosphate donor for phosphorylation reactions—was unraveled by Jefferson researchers. Their studies revealed a new model of kinase regulation, whereby ATP modulates an “on-off-switch” mechanism in Akt by inducing conformational changes in the Akt kinase domain. The three members of the Akt …

21
Jun

Dr. Karen Knudsen and Dr. Renato Iozzo receive Distinguished Mentor Awards.

On Monday, June 11, 2012, at the Annual Jefferson Postdoctoral Research Symposium, Dr. Karen Knudsen and Dr. Renato Iozzo were honored with The Distinguished Mentor Award. The Distinguished Mentor Award was established to recognize Jefferson faculty members that excel in the mentoring of postdoctoral fellows. The award also serves to highlight the importance of positive and …

14
Jun

How Aging Normal Cells Fuel Tumor Growth and Metastasis

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive. Now, researchers at the Kimmel Cancer Center at Jefferson (KCC) have shown that senescence (aging cells which lose their ability to divide) and autophagy (self-eating or self-cannibalism) in the surrounding normal cells of …

14
Jun

Kimmel Cancer Center at Jefferson Hosts a Patient Symposium Focusing on Melanoma of the Eye

The Kimmel Cancer Center will host the inaugural “Eyes on a Cure: Patient and Caregiver Symposium”  on June 16 and 17. The symposium will bring uveal melanoma patients, caregivers, and researchers from around the world together to offer educational sessions, support groups led by oncology social workers, sessions on complementary therapies, as well as informal …

13
Jun

HIV Drug May Slow Down Metastatic Triple-Negative Breast Cancer

Researchers at the Kimmel Cancer Center, led by Dr. Richard G. Pestell have discovered that FDA-approved HIV drugs may stop triple-negative breast cancer from spreading to other organs in pre-clinical models. These results were originally reported in Cancer Research. Recent articles about this discovery have also appeared in NewsWise and the Philadelphia Inquirer.

12
Jun

Jefferson Kimmel Cancer Center Tribute Dinner Honoring Steve Sabol, President of NFL Films

On Tuesday, June 5, 2012, the Kimmel Cancer Center at Jefferson and 300 guests honored Steve Sabol, President for NFL Films benefiting cancer research and patient care at the Union League of Philadelphia. The evening’s remarks were delivered by Sidney and Caroline Kimmel; and NFL Films special guests, Greg Cosell, and Pat Kelleher. Also in …

7
Jun

HIV drug may slow down metastatic breast cancer

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research. Such drugs target the HIV receptor CCR5, which the virus uses to enter and infect host cells, and …

31
May

ASCO: Younger Colon Cancer Patients Have Worse Prognosis at Diagnosis, Yet Better Survival

Younger patients with colorectal cancer were more likely to present advanced stage tumors at diagnosis and metastasize much sooner, yet had better than or equal survival to patients 50 and older, according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, Monday, June 4, 8:00 AM …

31
May

ASCO: Liver Metastases and its Prognostic Significance in Men With Metastatic Castration-Refractory Prostate Cancer

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655, Sunday, June 3, 8:00 AM – 12:00 PM CST, S Hall A2). In a phase III trial, lead study author William …

23
May

Data Continues to Support Provenge’s Overall Survival Benefit in Prostate Cancer Patients

This article was adapted from an OncLive story posted on May 21, 2012. Leonard G. Gomella, M.D, chair of the Department of Urology at Thomas Jefferson University Hospital and director of Clinical Affairs, Jefferson’s Kimmel Cancer Center, was part of the team to present new findings from the IMPACT trial looking at the immunotherapy sipuleucel-T …

22
May

Jefferson’s Kimmel Cancer Center to Host Tribute Dinner Honoring Steve Sabol, President of NFL Films

Jefferson’s Kimmel Cancer Center will host a tribute dinner to honor legendary filmmaker Steve Sabol, President of NFL Films, with the Spirit of Courage Award at the Union League of Philadelphia on June 5. The award is presented to an individual who has demonstrated great personal courage, strength and dignity while battling cancer and supporting …

16
May

Jefferson Receives $2.6 Million NIH Grant to Study Imaging Method to Stage Prostate Cancer Without Biopsy

Jefferson’s Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can …

10
May

A Closer Look at PARP-1 Reveals Potential New Drug Targets

A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. The investigation led by John M. Pascal, Ph.D., an assistant professor in the Department of Biochemistry and Molecular Biology …

8
May

Dr. Jeannie Hoffman-Censits leads Walk for Bladder Cancer

On Saturday, May 5, 2012 Jeannie Hoffman-Censits, M.D. led Team Jefferson from the Kimmel Cancer Center‘s Bluemle Life Sciences Building to Independence Hall. Dr. Hoffman-Censits teamed up with “the first national advocacy organization devoted to bladder cancer,” the Bladder Cancer Advocacy Network, to help raise public awareness of bladder cancer and much needed funding. Team …

7
May

Dr. Ronald Myers selected to chair Expert Working Group discussion

Ronald Myers, Ph.D., Professor of Medical Oncology and Director of the Division of Population Science at Thomas Jefferson University, has been selected to chair an Expert Working Group discussion at the World Endoscopy Organization meeting on May 18, 2012. The discussion entitled “Improving Population Engagement in Screening” is being held ahead of the DDW Conference …

26
Apr

Scott Waldman Awarded CURE Grant to Move Colon Cancer Test Closer to Commercialization

Scott Waldman, M.D., Ph.D., Chair of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded a Commonwealth Universal Research Enhancement (CURE) grant for almost $750,000 to help advance a molecular diagnostic test for colon cancer into commercialization. Such a test would better detect recurrence in a group of colon cancer …

25
Apr

You Can Help Save PA Research Funding

For more than a decade, Pennsylvania’s Commonwealth Universal Research Enhancement Program (CURE) has supported a broad range of biomedical research at 39 institutions across Pennsylvania. These funds have led to research advances in cancer, cardiovascular disease, diabetes, infectious diseases, and other health areas and improvements in public health. In his budget for fiscal year 2013, …

Page 1 of 21